LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

LLY

1,017.56

-3.18%↓

JNJ

248.4

-0.01%↓

ABBV

234.14

+0.93%↑

NVS

166.69

-0.97%↓

MRK

121.3

-1.96%↓

Search

Karyopharm Therapeutics Inc

Chiusa

SettoreSettore sanitario

9.58 2.68

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.75

Massimo

9.81

Metriche Chiave

By Trading Economics

Entrata

-69M

-102M

Vendite

-10M

34M

EPS

-2.227

Margine di Profitto

-299.886

Dipendenti

228

EBITDA

4.7M

-18M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+77.15% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

27M

184M

Apertura precedente

6.9

Chiusura precedente

9.58

Notizie sul Sentiment di mercato

By Acuity

34%

66%

79 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Karyopharm Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 mar 2026, 23:41 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2 mar 2026, 23:37 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2 mar 2026, 23:26 UTC

Principali Notizie su Eventi

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2 mar 2026, 22:41 UTC

Discorsi di Mercato

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2 mar 2026, 22:32 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:32 UTC

Discorsi di Mercato

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2 mar 2026, 22:21 UTC

Discorsi di Mercato

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2 mar 2026, 22:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 mar 2026, 22:11 UTC

Discorsi di Mercato

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2 mar 2026, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2 mar 2026, 22:06 UTC

Discorsi di Mercato

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2 mar 2026, 22:00 UTC

Discorsi di Mercato
Utili

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 22:00 UTC

Discorsi di Mercato
Utili

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2 mar 2026, 21:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Energy & Utilities Roundup: Market Talk

2 mar 2026, 21:50 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

2 mar 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

2 mar 2026, 21:35 UTC

Acquisizioni, Fusioni, Takeovers

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2 mar 2026, 21:34 UTC

Acquisizioni, Fusioni, Takeovers

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2 mar 2026, 21:30 UTC

Acquisizioni, Fusioni, Takeovers

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 21:17 UTC

Principali Notizie su Eventi

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2 mar 2026, 20:44 UTC

Utili

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:43 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Treasury Yields Fall, Dollar Strengthens After Attack on Iran -- Market Talk

2 mar 2026, 20:28 UTC

Utili

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2 mar 2026, 20:25 UTC

Discorsi di Mercato
Principali Notizie su Eventi

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2 mar 2026, 20:24 UTC

Utili

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2 mar 2026, 20:14 UTC

Acquisizioni, Fusioni, Takeovers

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2 mar 2026, 20:12 UTC

Principali Notizie su Eventi

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2 mar 2026, 20:08 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Global Forex and Fixed Income Roundup: Market Talk

2 mar 2026, 20:08 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2 mar 2026, 20:05 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Confronto tra pari

Modifica del prezzo

Karyopharm Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

77.15% in crescita

Previsioni per 12 mesi

Media 16.67 USD  77.15%

Alto 23 USD

Basso 12 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.9501 / 7.66Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

No Evidence

Sentiment

By Acuity

79 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

help-icon Live chat